Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Inhibikase Therapeutics (IKT) has 3 years of Current Deferred Revenue data on file, last reported at $23683.0 in Q3 2022.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $23683.0 in Q3 2022; TTM through Sep 2022 was $23683.0, a N/A change from a year earlier, with the FY2020 full-year figure at $2.3 million, changed N/A from the prior year.
• Current Deferred Revenue for Q3 2022 stood at $23683.0, roughly flat from $23684.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for IKT reached as high as $2.3 million in Q4 2020 and fell as low as $23683.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $753415.2 across 3 years, with a median of $142619.0 in 2021.
• On a YoY basis, Current Deferred Revenue climbed as much as 83.39% in 2022 and fell as far as 83.39% in 2022.
• Year by year, Current Deferred Revenue stood at $2.3 million in 2020, then slumped by 93.87% to $142619.0 in 2021, then tumbled by 83.39% to $23683.0 in 2022.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $23683.0 in Q3 2022, $23684.0 in Q2 2022, and $142619.0 in Q2 2021.